Matches in SemOpenAlex for { <https://semopenalex.org/work/W2521809735> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2521809735 endingPage "1209" @default.
- W2521809735 startingPage "1208" @default.
- W2521809735 abstract "L’atteinte interstitielle pulmonaire est présente chez presque un malade sur deux au cours de la sclérodermie systémique. Cette complication est fortement associée aux auto-anticorps anti-topoisomérase 1. Elle est toutefois évolutive chez seulement une faible proportion de ces patients et beaucoup d’initiatives actuellement cherchent à définir des facteurs prédictifs de progression. Les outils sont notamment la tomodensitométrie qui est très précise pour identifier des modifications du parenchyme et les explorations fonctionnelles respiratoires pour en définir les conséquences fonctionnelles. Les immunosuppresseurs synthétiques ont été beaucoup utilisés malgré la faible démonstration de leur efficacité. Si le cyclophosphamide oral a été le plus évalué, sa toxicité tend à imposer le mycophénolate mofétyl en traitement de première ligne. La sélection des malades à traiter reste l’objet de débat même si des critères simples basés sur le degré d’extension au scanner ont été proposés. Des traitements ciblés sont en cours d’évaluation notamment le tocilizumab et le rituximab. Des traitements anti-fibrosant sont également à l’étude, notamment la pirfénidone et le nintedanib qui sont autorisés dans la fibrose pulmonaire idiopathique. L’avenir pourrait être aux combinaisons de ces traitements qui apparaissent très complémentaires d’un point de vue physiopathologique.Interstitial lung disease complicates systemic sclerosis in about one out of 2 patients. This event is strongly associated with the presence of auto-antibodies anti-topoisomerase type 1. However, it is progressing in a small proportion of the affected patients and several studies are ongoing to try to identify predictive factors. Tools are primarily computed tomography that can stringently depict any interstitial lung changes and also pulmonary functional tests that can identify any functional consequences of these defects. Synthetic immunosuppressants have mostly been offered to affected patients so far despite the weak scientific demonstration of efficacy. If oral cyclophosphamide has been mostly investigated, its high toxicity makes mycophenolate mofetyl frequently the preferred drug as a first line therapy. Criteria to select the patients to be treated remain a matter of debate although simple criteria based on the extent of damages on CT-scan have been published. Targeted therapies are under evaluation with in particular clinical trials assessing tocilizumab and rituximab. Anti-fibrotic drugs are also under development with specifically pirfenidone and nintedanib which are on the market for idiopathic lung fibrosis. The future might be the combination of the above molecules that would appear very complementary taking into account disease pathogenesis." @default.
- W2521809735 created "2016-09-30" @default.
- W2521809735 creator A5001660061 @default.
- W2521809735 creator A5067355327 @default.
- W2521809735 creator A5074099993 @default.
- W2521809735 creator A5078873097 @default.
- W2521809735 date "2016-12-01" @default.
- W2521809735 modified "2023-10-16" @default.
- W2521809735 title "Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants" @default.
- W2521809735 cites W1567364560 @default.
- W2521809735 cites W1939859220 @default.
- W2521809735 cites W1975349041 @default.
- W2521809735 cites W2002025728 @default.
- W2521809735 cites W2021164865 @default.
- W2521809735 cites W2038650884 @default.
- W2521809735 cites W2054221721 @default.
- W2521809735 cites W2061364794 @default.
- W2521809735 cites W2061560222 @default.
- W2521809735 cites W2082968051 @default.
- W2521809735 cites W2099167708 @default.
- W2521809735 cites W2123700925 @default.
- W2521809735 cites W2170620123 @default.
- W2521809735 doi "https://doi.org/10.1016/j.autrev.2016.09.025" @default.
- W2521809735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27666817" @default.
- W2521809735 hasPublicationYear "2016" @default.
- W2521809735 type Work @default.
- W2521809735 sameAs 2521809735 @default.
- W2521809735 citedByCount "10" @default.
- W2521809735 countsByYear W25218097352017 @default.
- W2521809735 countsByYear W25218097352018 @default.
- W2521809735 countsByYear W25218097352019 @default.
- W2521809735 countsByYear W25218097352020 @default.
- W2521809735 countsByYear W25218097352022 @default.
- W2521809735 crossrefType "journal-article" @default.
- W2521809735 hasAuthorship W2521809735A5001660061 @default.
- W2521809735 hasAuthorship W2521809735A5067355327 @default.
- W2521809735 hasAuthorship W2521809735A5074099993 @default.
- W2521809735 hasAuthorship W2521809735A5078873097 @default.
- W2521809735 hasConcept C126322002 @default.
- W2521809735 hasConcept C2777543607 @default.
- W2521809735 hasConcept C2777714996 @default.
- W2521809735 hasConcept C29456083 @default.
- W2521809735 hasConcept C71924100 @default.
- W2521809735 hasConceptScore W2521809735C126322002 @default.
- W2521809735 hasConceptScore W2521809735C2777543607 @default.
- W2521809735 hasConceptScore W2521809735C2777714996 @default.
- W2521809735 hasConceptScore W2521809735C29456083 @default.
- W2521809735 hasConceptScore W2521809735C71924100 @default.
- W2521809735 hasIssue "12" @default.
- W2521809735 hasLocation W25218097351 @default.
- W2521809735 hasLocation W25218097352 @default.
- W2521809735 hasOpenAccess W2521809735 @default.
- W2521809735 hasPrimaryLocation W25218097351 @default.
- W2521809735 hasRelatedWork W1506200166 @default.
- W2521809735 hasRelatedWork W1995515455 @default.
- W2521809735 hasRelatedWork W2048182022 @default.
- W2521809735 hasRelatedWork W2080531066 @default.
- W2521809735 hasRelatedWork W2748952813 @default.
- W2521809735 hasRelatedWork W2765985895 @default.
- W2521809735 hasRelatedWork W2899084033 @default.
- W2521809735 hasRelatedWork W3031052312 @default.
- W2521809735 hasRelatedWork W3032375762 @default.
- W2521809735 hasRelatedWork W3108674512 @default.
- W2521809735 hasVolume "15" @default.
- W2521809735 isParatext "false" @default.
- W2521809735 isRetracted "false" @default.
- W2521809735 magId "2521809735" @default.
- W2521809735 workType "article" @default.